Alnylam Pharmaceuticals | ALNY - Assets


Alnylam Pharmaceuticals reported $5.56B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026